Hope for uterine cancer patients who don’t respond to chemotherapy

Hope for uterine cancer patients unresponsive to chemotherapy as first new treatment in 30 years approved

  • Hundreds of women with aggressive womb cancer will benefit from the first new treatment in 30 years, the NHS announced yesterday
  • He announced that some patients with advanced endometrial cancer will be offered the immunotherapy drug Dostarlimab
  • About 100 women a year who have uterine cancer that does not respond to chemotherapy will benefit from the treatment










Hundreds of women with aggressive womb cancer will benefit from the first new treatment in 30 years, the NHS announced yesterday.

He announced that some patients with advanced endometrial cancer – affecting the lining of the womb – would be offered the immunotherapy drug Dostarlimab after it was approved by the health watchdog.

About 100 women a year who have uterine cancer that does not respond to chemotherapy will benefit from the treatment.

Hundreds of women with aggressive womb cancer will benefit from the first new treatment in 30 years, the NHS announced yesterday

It stimulates the immune system to kill cancer cells.

The drug will be offered when the cancer has a specific change in DNA – which is around one in four cases of uterine cancer. Professor Stephen Powis of NHS England called it a “meaningful moment”. Endometrial cancer kills 2,400 Britons a year.

But one trial shows that Dostarlimab succeeded in shrinking or stabilizing tumors in 57% of patients, adding months or years to their lives.

The new treatment is administered intravenously in one 30-minute session, every three weeks over a 12-week period.

The new treatment is given intravenously in one 30-minute session, every three weeks over a 12-week period

The new treatment is given intravenously in one 30-minute session, every three weeks over a 12-week period

Professor Powis said: “This is an important moment for patients with advanced or recurrent endometrial cancer, as this new drug gives real hope to the approximately 100 patients a year who have had limited success with other treatments, taking just four 30-minute sessions, meaning it’s also less invasive.

Dr Eleanor Jones, of the Peaches Womb Cancer Trust, said: ‘Every year thousands of people across the UK are faced with the overwhelming reality of being diagnosed with endometrial cancer.

“For people with advanced cancer, there are still relatively few treatment options that could improve their lives or their prognosis.

“Today’s decision is truly welcome news and we hope it is just the start of wider progress in the treatment and care of those affected by this devastating cancer.”

Health and Social Care Secretary Sajid Javid said: ‘Our NHS continues to roll out the most innovative treatments from around the world for the benefit of patients, and this new treatment for endometrial cancer – the first in the gender – will offer hope to hundreds of women. ‘

Advertising

Comments are closed.